Inclusion Criteria:
1. Male/female participants who are at least 18 years of age on the day of signing
informed consent with histologically confirmed diagnosis of PD1 mRNA high-expression
(cohort 1, 3) or PD1 mRNA low-expression (cohort 2) determined on the tumor sample
will be enrolled in this study. Enrollment of patients > 75 years of age is allowed
after consultation and approval of the study medical monitor.
2. Life expectancy > 3 months as per investigator opinion.
3. The participant (or legally acceptable representative if applicable) provides
written specific informed consent for the remaining screening tests and study
procedures before inclusion in the trial.
4. Have measurable disease based on RECIST 1.1 or RANO criteria, as appropriate to
tumor type. Lesions situated in a previously irradiated area are considered
measurable if progression has been demonstrated in such lesions.
5. Have radiologic evidence of disease progression or recurrence after the previous
oncologic treatment. 6. Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
Evaluation of ECOG is to be performed within 10 days prior to the date of
allocation.
7. Have adequate organ function. Specimens must be collected within 28 days prior to
the start of study treatment.
8. Patients could have received a maximum of 3 lines of prior standard of care
chemotherapy in the inoperable/metastatic setting.
9. Treatment-related toxicities (except alopecia) must ≤ Grade 1 at the time of
allocation according to CTCAE version 5.0.
Exclusion Criteria:
1. A Women of childbearing potential who has a positive urine pregnancy test within 72
hours prior to allocation. If the urine test is positive or cannot be confirmed as
negative, a serum pregnancy test will be required.
Note: in the event that 72 hours have elapsed between the screening pregnancy test
and the first dose of study treatment, another pregnancy test (urine or serum) must
be performed and must be negative in order for subject to start receiving study
medication.
2. Has received prior therapy with an anti-PD1, anti-PDL1, or anti-PDL2 agent or with
an agent directed to another stimulatory or co-inhibitory T-cell receptor.
3. Has received prior systemic anti-cancer therapy, including investigational agents
within 2 weeks. Medical Monitor could consider shorter interval for kinase
inhibitors or other short half-life drugs prior to allocation.
Note: Participants must have recovered from all AEs due to previous therapies to
≤Grade 1 or baseline according to CTCAE version 5.0 (except alopecia). Participants
with ≤Grade 2 neuropathy may be eligible.
Note: If participant received major surgery, they must have recovered adequately
from the toxicity and/or complications from the intervention prior to starting study
treatment.
4. Has received prior radiotherapy within 2 weeks of start of study treatment.
Participants must have recovered from all radiation-related toxicities, not require
corticosteroids and not have had radiation pneumonitis. A 1-week washout is
permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.
5. Use of any live vaccines against infectious diseases within 4 weeks of initiation of
study treatment.
6. Is currently participating in or has participated in a study of an investigational
agent or has used an investigational device within 2 weeks prior to the first dose
of study treatment.
Note: Participants who have entered the follow-up phase of an investigational study
may participate as long as it has been 2 weeks after the last dose of the previous
investigational agent.
7. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
(in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
immunosuppressive therapy within 7 days prior to the first dose of study drug.
8. Has a known additional malignancy that is progressing or has required active
treatment within the past 3 years.
Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of
the skin or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that
have undergone potentially curative therapy are not excluded.
9. Patients with thymoma are not eligible. Patients with active CNS metastases and/or
carcinomatous meningitis are not eligible. Subjects with up to three cerebral
metastases are eligible, if all lesions are stable and have been definitively
treated with stereotactic radiation therapy, surgery or gamma knife therapy with no
evidence of disease progression for at least 4 weeks by repeat imaging (note that
the repeat imaging should be performed during study screening), clinically stable
and without requirement of steroid treatment for at least 14 days prior to first
dose of study treatment.
10. Has severe hypersensitivity (≥Grade 3) to Spartalizumab or Tislelizumab and/or any
of its excipients.
11. History of severe hypersensitivity reactions to other monoclonal antibodies, which
in the opinion of the investigator may pose an increased risk of serious infusion
reaction.
12. Has active autoimmune disease that has required systemic treatment in the past 2
years (i.e. with use of disease modifying agents, corticosteroids or
immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or
physiologic corticosteroid replacement therapy for adrenal or pituitary
insufficiency, etc.) is not considered a form of systemic treatment.
13. Prior allogeneic stem cell transplantation or organ transplantation. 14. Has a history of interstitial lung disease, (non-infectious) pneumonitis that
required steroids or has current pneumonitis, uncontrolled lung including pulmonary
fibrosis, acute lung diseases, etc. Patients with significantly impaired pulmonary
function, or who require supplemental oxygen at baseline must undergo an assessment
of pulmonary function at screening.
15. Has an active infection requiring systemic therapy.
16. Has a known history of Human Immunodeficiency Virus (HIV).
17. Has a known history of Hepatitis B (defined as Hepatitis B surface antigen [HBsAg]
reactive) or known active Hepatitis C virus (defined as HCV RNA is detected)
infection.
18. Has a known history of active TBC (Bacillus Tuberculosis).
19. Has a history or current evidence of any condition, therapy, or laboratory
abnormality that might confound the results of the study, interfere with the
subject's participation for the full duration of the study, or is not in the best
interest of the subject to participate, in the opinion of the treating investigator.
20. Has known psychiatric or substance abuse disorders that would interfere with
cooperation with the requirements of the trial.
21. Is pregnant or breastfeeding or expecting to conceive or father children within the
projected duration of the study, starting with the screening visit through 150 days
after the last dose of trial treatment.
22. Women of child-bearing potential, defined as all women physiologically capable of
becoming pregnant, unless they are using highly effective methods of contraception
during dosing and for 150-days after stopping treatment with spartalizumab or
tislelizumab. Highly effective contraception methods include:
1. Total abstinence (when this is in line with the preferred and usual lifestyle
of the subject). Periodic abstinence (e.g., calendar, ovulation, symptothermal,
post-ovulation methods) and withdrawal are not acceptable methods of
contraception.
2. Female sterilization (have had surgical bilateral oophorectomy with or without
hysterectomy), total hysterectomy, or tubal ligation at least six weeks before
taking study treatment. In case of oophorectomy alone, only when the
reproductive status of the woman has been confirmed by follow up hormone level
assessment.
3. Male sterilization (at least 6 months prior to screening). The vasectomized
male partner should be the sole partner for that subject.
4. Placement of a non-hormonal intrauterine device (IUD) or intrauterine system
(IUS) with a documented failure rate of less than 1% per year.
Notes:
- - Double-barrier contraception: condom and occlusive cap (diaphragm or
cervical/vault caps) with a vaginal spermicidal agent
(foam/gel/cream/suppository) are not considered highly effective methods of
contraception.
- - Women are considered post-menopausal and not of child bearing potential if they
have had 12 months of natural (spontaneous) amenorrhea with an appropriate
clinical profile (i.e. age appropriate, history of vasomotor symptoms) or have
had surgical bilateral oophorectomy (with or without hysterectomy), total
hysterectomy, or tubal ligation at least six weeks ago.
In the case of
oophorectomy alone, only when the reproductive status of the woman has been
confirmed by follow up hormone level assessment is she considered not of child
bearing potential.
23. Sexually active males, unless they use a condom during intercourse while on
treatment and for 150 days after stopping treatment with spartalizumab or
tislelizumab should not father a child in this period. A condom is required to be
used by vasectomized men as well during intercourse in order to prevent delivery of
the drug via semen.
